Zoetis Inc.

Valuation Analysis

About the Company

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and

Zoetis Inc. Stock at a Glance

Zoetis Inc. (ZTS) is currently trading at $79.57 with a market capitalization of $33.4B. The trailing P/E ratio stands at 13.04x, with a forward P/E of 10.72x. The 52-week range spans from $72.38 to $166.77; the current price is 52.3% below the yearly high. Year-over-year revenue growth stands at +2.9%. The net profit margin stands at 28.04%.

💰 Dividend

Zoetis Inc. pays an annual dividend of $2.12 per share, representing a yield of 2.66%. The payout ratio stands at 33.28%.

📊 Analyst Rating

17 analysts rate Zoetis Inc. (ZTS) on consensus: Buy. The average price target is $124.59, implying +56.58% from the current price. Analyst price targets range from $90.00 to $160.00.

Zoetis Inc.: The Investment Case in Detail

Zoetis Inc. (ZTS) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

With a gross margin near 71.84%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 67.75% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard. Free cash flow is positive and net margins stand at 28.04%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

The Bear Case

Revenue growth has slowed to just 2.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy. The debt-to-equity ratio of 286.24% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valuation in Context

The EV/EBITDA multiple of 9.98x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 10.72x is meaningfully below the trailing 13.04x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 56.58% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Zoetis Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.